New vaccine aims to stop lung cancer from coming back
NCT ID NCT05642195
First seen Sep 30, 2025 · Last updated Jun 14, 2026 · Updated 39 times
Summary
This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer and whose tumors are PD-L1 negative. The goal is to see if the vaccine can train the immune system to recognize and destroy any remaining cancer cells, preventing the cancer from returning. About 30 adults with no signs of cancer after surgery will receive the vaccine with or without N-803 over several months and be followed for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.